Xanomeline and Trospium Chloride
Brand Names: Cobenfy
Methodology & AI Transparency ⓘ
Xanomeline and Trospium Chloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Supplied in 50 mg/1 / 20 mg/1 Capsule, Coated Pellets and Kit and manufactured/labeled by E.R.
- 2 Real-world patient consensus: Tracked across 19 patient dosage logs with a 91% satisfaction benchmark (RxCUI RXN-00030050-2302).
- 3 Typical cash cost range: Public pharmacy ledger: $185.00 low cash benchmark vs. $453.25 chain retail average ($29.7103/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Xanomeline and Trospium Chloride tolerability events: nausea (8.6%), headache (7.1%), dizziness (5.1%).
Ask our AI Specialists anything about Xanomeline and Trospium Chloride
Xanomeline and Trospium Chloride Mechanism, CYP450 Pathways & DailyMed Monograph
Supplied in 50 mg/1 / 20 mg/1 Capsule, Coated Pellets and Kit and manufactured/labeled by E.R. Squibb & Sons, L.L.C. (NDC 0003-0050, 0003-5150), Xanomeline and Trospium Chloride operates within oral-route cholinergic muscarinic agonist treatment algorithms requiring prescription authorization.
Delivered via 50 mg/1 / 20 mg/1 Capsule, Coated Pellets and Kit (oral-route; NDC 0003-0050, 0003-5150), Xanomeline and Trospium Chloride mediates cholinergic muscarinic agonist physiological effects manufactured/labeled by E.R. Squibb & Sons, L.L.C. with dose-dependent receptor occupancy and systemic clearance.
Systemic exposure to Xanomeline and Trospium Chloride reflects Systemic oral bioavailability of roughly 69%–81% following first-pass transit absorption kinetics and hepatic enzymatic processing and renal clearance proportional to creatinine clearance (xanomeline and trospium chloride), sustaining receptor engagement across a Biphasic clearance with 5–13 hr terminal t½ under Xanomeline and Trospium Chloride maintenance half-life window (initial pharmacodynamic onset within 1–4 hrs (peak cmax) for xanomeline and trospium chloride response profile).
Dosing protocols (50 mg/1 / 20 mg/1 Capsule, Coated Pellets or Kit or 125 mg/1 / 30 mg/1 Capsule, Coated Pellets or 100 mg/1 / 20 mg/1 Capsule, Coated Pellets) balance efficacy (91.00% patient satisfaction across 19 logs) against nausea (8.6% of reports), headache (7.1% of reports), fatigue (5.4% of reports), with strict avoidance in documented intolerance or hypersensitivity reaction involving xanomeline and trospium chloride (cholinergic muscarinic agonist); concurrent restricted medications flagged in section 4/7 of the xanomeline and trospium chloride dailymed monograph (rxn-00030050-2302).
Assess baseline hepatic panels and interacting prescriptions when starting Xanomeline and Trospium Chloride (cholinergic muscarinic agonist).
Botanical enzyme modulators may alter oral first-pass exposure of Xanomeline and Trospium Chloride; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Xanomeline and Trospium Chloride (cholinergic muscarinic agonist)
- Concurrent restricted medications flagged in Section 4/7 of the Xanomeline and Trospium Chloride DailyMed monograph (RXN-00030050-2302)
Logged Side-Effect Incidence (19 Reports)
Xanomeline and Trospium Chloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Xanomeline and Trospium Chloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute: What a 357-Participant Study Found Participants with acute schizophrenia with prespecified impairments demonstrated significant cognitive improvement with xanomeline/trospium compared with placebo. The American journal of psychiatry • 2025-03-01 • Phase III Randomized Trial | N = 357 | 93/100 | PMID 39659157 ↗ |
| New Insights on Long-Term safety and real-world benefits of Xanomeline and Trospium Chloride in: What a 366-Participant Study Found Long-term treatment with X/T over 52 weeks was safe, generally well tolerated, and associated with durable symptom improvement in people with schizophrenia. The American journal of psychiatry • 2026-03-01 • Phase III Randomized Trial | N = 366 | 93/100 | PMID 41634905 ↗ |
Xanomeline and Trospium Chloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $29.7103/unit (~$891.31/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Xanomeline and Trospium Chloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Xanomeline and Trospium Chloride RxNorm Concept ID | RXN-00030050-2302 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $29.7103 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Xanomeline and Trospium Chloride Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Xanomeline and Trospium Chloride integrating DailyMed SPL (2026-07-01), CMS NADAC ($29.7103/unit), and 19 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Xanomeline and Trospium Chloride community threads and patient logs by age, biological sex, dosage, and treatment duration.